Prothena Corp Stock (NASDAQ:PRTA), Trade Ideas

Prothena Corp

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADXN

AEON

AGFY

ALRN

Adtalem Global Education Inc. Common Stock

ATGE

ATPC

BCLI

BORR

CALX

CISS

CNSP

CVLT

IFBD

IMCC

KURA

MBIN

MBUU

MOTS

NVVE

NYAX

NYXH

ONMD

PALI

PRTA

PTPI

PXLW

REVB

RVSN

SANM

SIDU

SLNA

SWIN

SXTP

TIVC

WFRD

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales 

Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

CYBR

GRFS

HOLX

HRTX

JNPR

MCHP

NKTX

SMMT

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 100 points on Tuesday.

Shares of  Hewlett Packard Enterprise Company (NYSE: HPE) shares fell sharply in pre-market trading on Tuesday.

Hewlett Packard Enterprise, Hologic And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

AMAM

AMPE

ARBK

ARDX

AREN

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXNX

BCRX

BFLY

BNZI

BSGM

CROX

CYCC

DADA

DVAX

ELEV

FSLY

HARP

LMDX

NEXI

PACB

PRAX

RGNX

RVNC

RXST

SHPH

SILK

SNMP

SPEC

STSS

STTK

TCJH

TREE

UPWK

VERO

VINC

ZJYL

Shares of  RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.

Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The publication can be found in the latest issue of Leukemia &amp; Lymphoma, an international peer-reviewed journal that publishes research on all aspects of hematological malignancies.
AL amyloidosis is an idiopathic, rare, progressive and often fatal disease characterized by amyloid deposits that build up in vital organs leading to damage, dysfunction and failure. The risk of early mortality is especially high in patients with significant cardiac involvement as there are no current treatment options that target existing amyloid deposits in these patients.
Birtamimab binds to a highly conserved cryptic epitope which is only exposed in misfolded kappa and lambda light chain (LC) protein. Birtamimab binds and neutralizes soluble, toxic LC aggregates and binds and clears insoluble AL amyloid deposits, without affecting normally folded LC proteins. This mechanism of action is complementary to the current standard of care therapy for AL amyloidosis which does not target the existing toxic LC aggregates and amyloid deposits.
"Birtamimab was designed to clear deposited amyloid from vital organs and is the only treatment that has shown a significant survival benefit in patients with Mayo Stage IV AL amyloidosis, which was demonstrated in a post hoc analysis of the Phase 3 VITAL placebo-controlled clinical trial," said Hideki Garren, M.D., Ph.D., Chief Medical Officer, Prothena. "Birtamimab is being evaluated in patients with Mayo Stage IV AL amyloidosis, who are at high risk of early mortality, in the ongoing confirmatory Phase 3 AFFIRM-AL clinical trial."
A copy of the peer-reviewed article can be found here in Leukemia &amp; Lymphoma:

Biotech

General

Prothena Announces Review On Birtamimab Mechanism Of Action And Pharmacological Characteristics Published In Leukemia & Lymphoma

Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Overweight.

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Prothena Corp

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $72.5, a high estimate of $129.00, and a low estimate of $35.00. Observing a downward trend, the current average is 6.88% lower than the prior average price target of $77.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1710338436_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$85.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$36.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$129.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Prothena Corp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Prothena Corp's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Prothena Corp</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Prothena Corp: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Prothena Corp's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -99.37% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -21353.16%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Prothena Corp's ROE stands out, surpassing industry averages. With an impressive ROE of -11.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Prothena Corp's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.35%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Prothena Corp's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Prothena Corp: Insights From 8 Analyst Reviews

HC Wainwright &amp; Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $90 price target.

Price Target

HC Wainwright & Co. Maintains Buy on Prothena Corp, Maintains $90 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.50</td>
<td>$80.7K</td>
<td>7.9K</td>
<td>4.8K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/08/24</td>
<td>$75.00</td>
<td>$36.8K</td>
<td>2.8K</td>
<td>2.1K</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$20.00</td>
<td>$40.8K</td>
<td>3.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/01/24</td>
<td>$82.00</td>
<td>$26.0K</td>
<td>10</td>
<td>274</td>
</tr>
<tr>
<td>MOH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/15/24</td>
<td>$390.00</td>
<td>$26.1K</td>
<td>31</td>
<td>200</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/19/24</td>
<td>$750.00</td>
<td>$32.2K</td>
<td>489</td>
<td>191</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$200.00</td>
<td>$78.4K</td>
<td>423</td>
<td>138</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/15/24</td>
<td>$32.50</td>
<td>$43.2K</td>
<td>109</td>
<td>125</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$420.00</td>
<td>$178.8K</td>
<td>0</td>
<td>120</td>
</tr>
<tr>
<td>PRTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$25.00</td>
<td>$33.0K</td>
<td>2</td>
<td>92</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For NVAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), we notice a put option sweep that happens to be bearish, expiring in 687 day(s) on January 16, 2026. This event was a transfer of 909 contract(s) at a $2.50 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $80.7K, with a price of $89.0 per contract. There were 7911 open contracts at this strike prior to today, and today 4853 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bullish, expiring in 8 day(s) on March 8, 2024. This event was a transfer of 206 contract(s) at a $75.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $36.8K, with a price of $179.0 per contract. There were 2859 open contracts at this strike prior to today, and today 2143 contract(s) were bought and sold. 
• For IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on April 19, 2024. This event was a transfer of 627 contract(s) at a $20.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $40.8K, with a price of $65.0 per contract. There were 3429 open contracts at this strike prior to today, and today 1106 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with bullish sentiment. It expires in 1 day(s) on March 1, 2024. Parties traded 100 contract(s) at a $82.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $260.0 per contract. There were 10 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• For MOH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), we notice a put option trade that happens to be bullish, expiring in 15 day(s) on March 15, 2024. This event was a transfer of 45 contract(s) at a $390.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $580.0 per contract. There were 31 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be neutral, expiring in 50 day(s) on April 19, 2024. This event was a transfer of 9 contract(s) at a $750.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $3580.0 per contract. There were 489 open contracts at this strike prior to today, and today 191 contract(s) were bought and sold. 
• For ALNY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), we notice a call option sweep that happens to be bearish, expiring in 204 day(s) on September 20, 2024. This event was a transfer of 59 contract(s) at a $200.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $78.4K, with a price of $1330.0 per contract. There were 423 open contracts at this strike prior to today, and today 138 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option sweep that happens to be bullish, expiring in 15 day(s) on March 15, 2024. This event was a transfer of 184 contract(s) at a $32.50 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $43.2K, with a price of $235.0 per contract. There were 109 open contracts at this strike prior to today, and today 125 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bullish, expiring in 477 day(s) on June 20, 2025. This event was a transfer of 120 contract(s) at a $420.00 strike. The total cost received by the writing party (or parties) was $178.8K, with a price of $1490.0 per contract. There were 0 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For PRTA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), we notice a call option trade that happens to be bullish, expiring in 113 day(s) on June 21, 2024. This event was a transfer of 50 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $660.0 per contract. There were 2 open contracts at this strike prior to today, and today 92 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

ALNY

IOVA

NVAX

VKTX

10 Health Care Stocks Whale Activity In Today's Session

JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Market Outperform and raises the price target from $81 to $85.

JMP Securities Maintains Market Outperform on Prothena Corp, Raises Price Target to $85

In the latest quarter, 6 analysts provided ratings for Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $64.5, a high estimate of $129.00, and a low estimate of $35.00. This current average represents a 6.52% decrease from the previous average price target of $69.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1708110037_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$36.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$129.00</td>
<td>-</td>
</tr>
<tr>
<td>Neena Bitritto-Garg</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$62.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Prothena Corp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Prothena Corp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Prothena Corp Better</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Prothena Corp's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Prothena Corp showcased positive performance, achieving a revenue growth rate of 5494.33% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 25.81%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Prothena Corp's ROE excels beyond industry benchmarks, reaching 3.65%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Prothena Corp's ROA stands out, surpassing industry averages. With an impressive ROA of 2.99%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Prothena Corp's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 6 Analyst Evaluations For Prothena Corp

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Sector Perform and lowers the price target from $36 to $35.

RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $35

Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.22) by 3.28 percent. This is a 1150 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $316.00 thousand which missed the analyst consensus estimate of $2.15 million by 85.32 percent. This is a 99.37 percent decrease over sales of $49.92 million the same period last year.

Earnings

Earnings Misses

Prothena Corp Q4 2023 GAAP EPS $(1.26) Misses $(1.22) Estimate, Sales $316.00K Miss $2.15M Estimate

Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Prothena Corp missed estimated earnings by 3.28%, reporting an EPS of $-1.26 versus an estimate of $-1.22.
Revenue was down $49.61 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.7 which was followed by a 7.41% increase in the share price the next day.
Here's a look at Prothena Corp's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.32</td>
<td>-1</td>
<td>-0.94</td>
<td>-0.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.38</td>
<td>-1.03</td>
<td>-0.89</td>
<td>0.12</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>41.69M</td>
<td>4.52M</td>
<td>7.37M</td>
<td>29.14M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>84.87M</td>
<td>4.02M</td>
<td>2.17M</td>
<td>49.92M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Prothena Corp <a href="https://www.benzinga.com/quote/PRTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Prothena Corp: Q4 Earnings Insights

Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here's what investors need to know before the announcement.
Analysts estimate that Prothena Corp will report an earnings per share (EPS) of $-1.22. 
Prothena Corp bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.70, which was followed by a 7.41% increase in the share price the next day.
Here's a look at Prothena Corp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.32</td>
<td>-1</td>
<td>-0.94</td>
<td>-0.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.38</td>
<td>-1.03</td>
<td>-0.89</td>
<td>0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.41%</td>
<td>-7.3%</td>
<td>12.02%</td>
<td>7.11%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707926529_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Prothena Corp were trading at $26.49 as of February 13. Over the last 52-week period, shares are down 48.48%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRTA/earnings">To track all earnings releases for Prothena Corp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Prothena Corp

WIIM

Prothena shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and lowered its price target from $68 to $38.

B of A Securities analyst Tazeen Ahmad downgrades Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from Buy to Neutral and lowers the price target from $68 to $38.

Downgrades

B of A Securities Downgrades Prothena Corp to Neutral, Lowers Price Target to $38

In the preceding three months, 5 analysts have released ratings for Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $79.0, a high estimate of $129.00, and a low estimate of $36.00. Observing a downward trend, the current average is 7.06% lower than the prior average price target of $85.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1706202017_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Prothena Corp's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$36.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$129.00</td>
<td>-</td>
</tr>
<tr>
<td>Neena Bitritto-Garg</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$81.00</td>
<td>$83.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Prothena Corp. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Prothena Corp's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Prothena Corp's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Prothena Corp</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Financial Insights: Prothena Corp</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Prothena Corp's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 5494.33%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Prothena Corp's net margin is impressive, surpassing industry averages. With a net margin of 25.81%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Prothena Corp's ROE stands out, surpassing industry averages. With an impressive ROE of 3.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Prothena Corp's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.99% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Prothena Corp's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 5 Analyst Ratings For Prothena Corp

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Sector Perform and lowers the price target from $43 to $36.

RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $36

Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) has outperformed the market over the past 5 years by 10.5% on an annualized basis producing an average annual return of 23.23%. Currently, Prothena Corp has a market capitalization of $1.73 billion. 
Buying $100 In PRTA: If an investor had bought $100 of PRTA stock 5 years ago, it would be worth $293.08 today based on a price of $32.30 for PRTA at the time of writing.
<h3>Prothena Corp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1705955497_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Prothena Corp 5 Years Ago Would Be Worth This Much Today

Across the recent three months, 5 analysts have shared their insights on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $97.6, a high estimate of $129.00, and a low estimate of $62.00. A decline of 7.92% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1704834011_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$129.00</td>
<td>-</td>
</tr>
<tr>
<td>Neena Bitritto-Garg</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$81.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$129.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Prothena Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Prothena Corp's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Prothena Corp</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Prothena Corp: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Prothena Corp's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 5494.33%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Prothena Corp's net margin excels beyond industry benchmarks, reaching 25.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Prothena Corp's ROE excels beyond industry benchmarks, reaching 3.65%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.99%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Prothena Corp adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Prothena Corp: Insights From 5 Analyst Reviews

Cantor Fitzgerald analyst Charles Duncan maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Overweight and lowers the price target from $129 to $87.

Cantor Fitzgerald Maintains Overweight on Prothena Corp, Lowers Price Target to $87

Prothena shares are trading lower after the company provided a business update on portfolio programs.

<h3>Gainers</h3>
<ul>
<li>Harpoon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HARP#NASDAQ">HARP</a>) stock moved upwards by 112.4% to $22.41 during Monday's regular session. The market value of their outstanding shares is at $379.3 million. </li>
<li>Ambrx Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAM#NASDAQ">AMAM</a>) stock increased by 100.07% to $27.27. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) shares moved upwards by 52.14% to $9.22. The market value of their outstanding shares is at $452.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock increased by 38.31% to $2.31. The market value of their outstanding shares is at $8.3 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock moved upwards by 36.06% to $1.19. The company's market cap stands at $50.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock increased by 35.65% to $1.56. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LumiraDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMDX#NASDAQ">LMDX</a>) stock decreased by 45.6% to $0.02 during Monday's regular session. The company's market cap stands at $5.9 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares fell 19.17% to $6.75. The company's market cap stands at $592.7 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) stock fell 18.55% to $33.12. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares declined by 17.71% to $0.19. The company's market cap stands at $2.0 million. </li>
<li>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) stock declined by 16.6% to $7.84. The company's market cap stands at $2.0 billion. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares declined by 15.34% to $101.5. The market value of their outstanding shares is at $786.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Health Care Stocks Moving In Monday's Intraday Session

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Prothena (PRTA – Research Report), with a price target ...

RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)

In a report released today, Yasmeen Rahimi from Piper Sandler assigned a Buy rating to Prothena (PRTA – Research Report), with a price target of $9...

Piper Sandler Releases a Buy Rating on Prothena (PRTA)

Rudy Li, an analyst from Leerink Partners, maintained the Buy rating on Prothena (PRTA – Research Report). The associated price target is $80.00. R...

Buy Rating Affirmed on Prothena Amid Strong Pipeline Progress and Solid Financials

Prothena appoints Daniel G. Welch as Chair Designate

Prothena (PRTA) has released an update. Prothena Corporation plc has expanded its Board of Directors and appointed Daniel G. Welch as a director an...

Prothena Appoints Daniel G. Welch as New Board Chair

Prothena files to offer ordinary shares

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Prothena (PRTA – Research Report) today and set a price target of $94.00. The compa...

Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crinetics Pharmaceuticals (CRNX – Research Report), ...

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)

Labcorp expands Alzheimer's testing portfolio with new diagnostic

BIIB

BLTE

BMYMP

CRNX

ESAIY

ESALF

NONOF

RHHBF

RHHBY

RHHVF

Press Releases

Prothena to Participate in Upcoming Healthcare Conferences

Prothena to Report Third Quarter 2023 Financial Results on November 2

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Abivax

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical